Ensysce Biosciences (ENSC) Competitors $2.05 -0.01 (-0.49%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.10 +0.05 (+2.24%) As of 08/15/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENSC vs. CMMB, BCAB, PASG, ASBP, SYBX, HOTH, LPCN, LEXX, BLRX, and CASIShould you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Chemomab Therapeutics (CMMB), BioAtla (BCAB), Passage Bio (PASG), Aspire Biopharma (ASBP), Synlogic (SYBX), Hoth Therapeutics (HOTH), Lipocine (LPCN), Lexaria Bioscience (LEXX), BioLineRx (BLRX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. Ensysce Biosciences vs. Its Competitors Chemomab Therapeutics BioAtla Passage Bio Aspire Biopharma Synlogic Hoth Therapeutics Lipocine Lexaria Bioscience BioLineRx CASI Pharmaceuticals Ensysce Biosciences (NASDAQ:ENSC) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Do insiders and institutionals believe in ENSC or CMMB? 5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 7.9% of Ensysce Biosciences shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate ENSC or CMMB? Chemomab Therapeutics has a consensus target price of $8.50, indicating a potential upside of 813.98%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Ensysce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ENSC or CMMB? Ensysce Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Chemomab Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Does the media refer more to ENSC or CMMB? In the previous week, Chemomab Therapeutics had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 6 mentions for Chemomab Therapeutics and 5 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.70 beat Chemomab Therapeutics' score of 0.65 indicating that Ensysce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ensysce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher valuation & earnings, ENSC or CMMB? Ensysce Biosciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$5.21M1.17-$7.99M-$6.54-0.31Chemomab TherapeuticsN/AN/A-$13.94M-$0.76-1.22 Is ENSC or CMMB more profitable? Chemomab Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -88.76%. Chemomab Therapeutics' return on equity of -88.15% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-88.76% -167.23% -104.59% Chemomab Therapeutics N/A -88.15%-70.00% SummaryChemomab Therapeutics beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks. Get Ensysce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENSC vs. The Competition Export to ExcelMetricEnsysce BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.11M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-0.5120.3830.5825.12Price / Sales1.17356.76462.42114.82Price / CashN/A42.3037.4059.05Price / Book1.998.659.096.18Net Income-$7.99M-$54.65M$3.25B$264.89M7 Day Performance-5.96%6.58%7.32%4.18%1 Month Performance-5.09%7.54%5.41%1.99%1 Year Performance-66.51%13.73%30.66%24.22% Ensysce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENSCEnsysce Biosciences0.6358 of 5 stars$2.05-0.5%N/A-65.2%$6.11M$5.21M-0.5110News CoverageEarnings ReportAnalyst RevisionCMMBChemomab Therapeutics3.4671 of 5 stars$1.00-2.4%$8.50+750.0%-13.9%$19.33MN/A-1.3220News CoverageEarnings ReportUpcoming EarningsShort Interest ↓BCABBioAtla2.3292 of 5 stars$0.33+0.5%$5.00+1,408.3%-80.4%$19.28M$11M-0.2760News CoverageAnalyst DowngradeAnalyst RevisionPASGPassage Bio3.7952 of 5 stars$5.74flat$150.00+2,513.2%-55.4%$17.91MN/A-0.28130News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap DownASBPAspire BiopharmaN/A$0.36+1.2%N/AN/A$17.85MN/A0.00N/ANews CoverageEarnings ReportSYBXSynlogic0.9737 of 5 stars$1.50+1.4%N/A+4.2%$17.31M$10K-0.6080Short Interest ↑Gap UpHOTHHoth Therapeutics3.1195 of 5 stars$1.40+7.3%$4.00+185.7%+107.4%$17.24MN/A-1.234Earnings ReportShort Interest ↓Gap DownLPCNLipocine2.8967 of 5 stars$3.13-0.6%$9.00+187.5%-17.2%$16.85M$11.20M-3.0710News CoverageLEXXLexaria Bioscience3.7982 of 5 stars$0.88+2.9%$4.00+357.1%-74.0%$16.63M$460K-1.317News CoverageShort Interest ↓BLRXBioLineRx3.3221 of 5 stars$3.84-0.8%$26.00+577.1%-86.3%$16.50M$22.34M-0.4440News CoverageEarnings ReportGap DownCASICASI Pharmaceuticals4.0892 of 5 stars$1.95+51.2%$4.00+105.1%-63.7%$15.87M$31.37M-0.76180High Trading Volume Related Companies and Tools Related Companies CMMB Alternatives BCAB Alternatives PASG Alternatives ASBP Alternatives SYBX Alternatives HOTH Alternatives LPCN Alternatives LEXX Alternatives BLRX Alternatives CASI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENSC) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ensysce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.